1 August 2020 in Journal of Molecular Biology
1 December 2025 in Arteriosclerosis, Thrombosis, and Vascular Biology
The global rise in obesity underscores the urgent need for effective long-term weight-management strategies. Weight loss (WL) is extremely beneficial in combating obesity complications, justifying the great success of recent WL medications. However, most individuals trying to lose weight will fail to maintain a lower body weight. Weight regain following WL increases the risk of cardiovascular disease and mortality. Adipose tissue inflammation is a critical mediator of metabolic dysfunction in obesity, contributing to cardiovascular complications. In obesity, chronic low-grade inflammation, marked by immune infiltration and dysregulated adipocyte function, contributes to systemic insulin resistance and metabolic comorbidities. However, the adipose tissue response to WL and subsequent weight regain is distinct from that in non–weight-fluctuating obesity and far less studied. This review synthesizes current literature to elucidate the dynamic shifts in adipose tissue across the continuum of obesity, WL, and weight regain.
14 January 2025 in bioRxiv
Vascular diseases, including acute respiratory distress syndrome (ARDS) and atherosclerosis, are leading causes of global morbidity and mortality, underscoring the critical need for innovative therapies. While human genetics has uncovered specific molecular mechanisms in endothelial cells that drive acute and chronic vascular inflammation central to these conditions, effective in vivo strategies to spatiotemporally target these disease-causing pathways using therapeutic mRNAs remain limited. Here, we present a modular and tunable nanoparticle platform (PROGRAMMED nanoparticles) engineered to selectively deliver therapeutic mRNAs to target cells with distinct molecular signatures, such as inflamed endothelial cells expressing vascular cell adhesion molecule 1 (VCAM1). This approach restores key genetics-informed endothelial pathways implicated in disease, including the loss of Krüppel-like factor 2 (KLF2) in acute inflammation underlying ARDS and the suppression of phospholipid phosphatase 3 (PLPP3) in chronic inflammation driving atherosclerosis. In multiple preclinical models, these precision mRNA nanomedicine strategies demonstrated compelling therapeutic efficacy. VCAM1-targeting PROGRAMMED nanoparticles delivering KLF2 mRNA to inflamed lung microvascular endothelial cells significantly improved microvascular health and alleviated virus-induced ARDS. Similarly, PLPP3 mRNA delivery by VCAM1-targeting PROGRAMMED nanoparticles attenuated arterial inflammation, slowed atherosclerosis progression, and promoted regression of advanced plaques. This innovative platform offers a transformative approach for spatiotemporal mRNA therapies targeting inflamed endothelial cells, providing a minimally invasive and highly specific strategy to address acute and chronic vascular diseases. Moreover, the modularity of PROGRAMMED nanoparticles, particularly their ability to display diverse targeting motifs, holds substantial potential for addressing a broad spectrum of vascular complications and other diseases that require precise spatiotemporal correction of dysregulated genes.
12 August 2024 in Journal of Proteome Research
5 May 2026 in Atherosclerosis